



## Resource impact template

Resource impact

Published: 13 March 2024

www.nice.org.uk

NICE has produced a <u>resource impact template</u> that incorporates the following technology appraisal guidance for diabetic macular oedema:

- Ranibizumab for treating diabetic macular oedema (2023) NICE technology appraisal guidance 274
- <u>Aflibercept for treating diabetic macular oedema</u> (2015) NICE technology appraisal guidance 346
- <u>Faricimab for treating diabetic macular oedema</u> (2022) NICE technology appraisal guidance 799
- <u>Brolucizumab for treating diabetic macular oedema</u> (2022) NICE technology appraisal guidance 820
- Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (2024) NICE technology appraisal guidance 953.